Nuvation Bio Inc (NYSE: NUVB) kicked off on Friday, up 4.07% from the previous trading day, before settling in for the closing price of $2.21. Over the past 52 weeks, NUVB has traded in a range of $0.95-$4.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -501.14%. With a float of $227.21 million, this company’s outstanding shares have now reached $334.78 million.
Let’s determine the extent of company efficiency that accounts for 51 employees. In terms of profitability, gross margin is -3.53%, operating margin of -6632.37%, and the pretax margin is -30060.04%.
Nuvation Bio Inc (NUVB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 32.13%, while institutional ownership is 39.13%. The most recent insider transaction that took place on Oct 08 ’24, was worth 220,000. In this transaction Director of this company bought 100,000 shares at a rate of $2.20, taking the stock ownership to the 100,000 shares. Before that another transaction happened on Jun 25 ’24, when Company’s Director bought 277,895 for $2.97, making the entire transaction worth $825,348. This insider now owns 2,453,131 shares in total.
Nuvation Bio Inc (NUVB) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.09 earnings per share (EPS), higher than consensus estimate (set at -0.11) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -501.14% per share during the next fiscal year.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Take a look at Nuvation Bio Inc’s (NUVB) current performance indicators. Last quarter, stock had a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 556.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Looking closely at Nuvation Bio Inc (NYSE: NUVB), its last 5-days average volume was 1.96 million, which is a jump from its year-to-date volume of 1.43 million. As of the previous 9 days, the stock’s Stochastic %D was 29.74%. Additionally, its Average True Range was 0.16.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 15.23%, which indicates a significant decrease from 28.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.56% in the past 14 days, which was higher than the 69.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.61, while its 200-day Moving Average is $2.71. However, in the short run, Nuvation Bio Inc’s stock first resistance to watch stands at $2.34. Second resistance stands at $2.38. The third major resistance level sits at $2.44. If the price goes on to break the first support level at $2.24, it is likely to go to the next support level at $2.18. Now, if the price goes above the second support level, the third support stands at $2.14.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
The company with the Market Capitalisation of 801.35 million has total of 249,245K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -75,800 K annual income. Company’s last quarter sales were recorded 1,440 K and last quarter income was -462,490 K.
